Autism spectrum disorders (ASD) are a group of related neurodevelopmental diseases displaying significant genetic and phenotypic heterogeneity [1] [2] [3] [4] . Despite recent progress in understanding ASD genetics, the nature of phenotypic heterogeneity across probands is currently unclear 5, 6 . Likely genedisrupting (LGD) de novo mutations affecting the same gene often result in substantially different intellectual quotient (IQ) phenotypes. Nevertheless, we find that truncating mutations affecting the same exon frequently lead to strikingly similar intellectual phenotypes in unrelated simplex ASD probands. Analogous patterns are observed for several other important ASD phenotypes, suggesting that exons, rather than genes, often represent a unit of effective phenotypic impact for truncating mutations. We find that phenotypic effects are likely mediated by nonsense-mediated decay (NMD) of splicing isoforms and that autism phenotypes are usually triggered by relatively mild (15-30%) decreases in overall gene dosage. Notably, for genes with recurrent truncating mutations, predicted expression changes can be used to infer phenotypic consequences in individual ASD probands. As LGD mutations in the same exon lead to similar expression changes across human tissues, analogous phenotypic patterns may be also observed in other developmental disorders.
In this study, we focused on severely damaging, so-called likely gene-disrupting (LGD) mutations, which include nonsense, splice site, and frameshift variants. We used genetic and phenotypic data, including exome de novo mutations and corresponding phenotypes of ASD probands 7 , for more than 2,500 families from the Simons Simplex Collection (SSC). De novo LGD mutations are observed at significantly higher rates in SSC probands compared to unaffected siblings 8, 9 . This demonstrates a substantial contribution of these mutations to disease etiology in simplex ASD families, i.e. families with only a single affected child among siblings. We primarily considered in the paper the impact of de novo LGD mutations on several well-studied intellectual phenotypes: full-scale (FSIQ), nonverbal (NVIQ), and verbal (VIQ) intelligence quotients 8, 10, 11 . Notably, these scores are standardized by age and normalized across a broad range of phenotypes 7 . We first investigated the variability of intellectual phenotypes associated with de novo LGD mutations in the same gene. The IQ differences between probands with mutations in the same gene were slightly smaller than differences between all pairs of probands. Specifically, the mean pairwise differences for probands with mutations in the same gene were: 28.3 for FSIQ (~11% smaller compared to all pairs of ASD probands, Mann-Whitney U one-tail test P = 0.2), 25.7 NVIQ (~12% smaller, P = 0.14), and 34.9 VIQ points (~1.1% smaller, P = 0.5). We next explored whether probands with LGD mutations at similar locations within the same gene resulted, on average, in more similar phenotypes (Fig. 1) . Indeed, IQ differences between probands with LGD mutations ≤ 1000 base pairs apart, for example, were significantly smaller than differences between probands with more distant mutations; ≤ 1 kbp FSIQ/NVIQ/VIQ average difference 11.5, 10.4, 20.6 points; > 1 kbp average difference 31.4, 28.6, 37.5 points (MWU one-tail test P = 0.002, 0.005, 0.01). However, across the entire range of nucleotide distances between LGD mutations, we did not observe significant correlations between IQ differences and mutation proximity (FSIQ/NVIQ/VIQ Spearman's = 0.09, 0.1, 0.03, P = 0.5, 0.4, 0.8).
Figure 2:
Average difference in IQ between SSC probands. Each bar shows the average IQ difference between pairs of probands from different groups. From right to left, the bars represent the average IQ difference between pairs of probands in the entire SSC population (light green), between probands with de novo LGD mutations in the same gene (dark green), between probands with de novo LGD mutations in the same exon (red), between probands of the same gender and with de novo LGD mutations in the same exon (orange). Error bars represent the SEM.
To explain the observed patterns of phenotypic similarity, we next considered the exon-intron structure of target genes. Specifically, we investigated truncating mutations affecting the same exon in unrelated ASD probands; we took into account LGD mutations in the exon's coding sequence as well as disruptions of the exon's flanking canonical splice sites, since such splice site mutations should affect the same transcript isoforms (Supplementary Fig. 1) . Interestingly, the analysis of 16 unrelated ASD probands (8 pairs) with such mutations showed that they have strikingly more similar phenotypes (Fig. 2 , red bars) compared to probands with LGD mutations in the same gene (Fig. 2 , dark green bars); same exon FSIQ/NVIQ/VIQ average IQ difference 8.9, 8.3, 17.3 points, same gene average difference 28.3, 25.7, 34.9 points (Mann-Whitney U one-tail test P = 0.003, 0.005, 0.016). Notably, the phenotypic similarity only extended to truncating mutations in the same exon. The average IQ differences between probands with mutations in neighboring exons were not significantly different compared to mutations in nonneighboring exons (MWU one-tail test P = 0.6, 0.18, 0.8; Supplementary Fig. 2 ). Because of well-known gender differences in autism susceptibility [11] [12] [13] , we also compared IQ differences between probands of the same gender harboring truncating mutations in the same exon (Fig. 2, orange We next explored the relationship between phenotypic similarity and the proximity of truncating mutations in the corresponding protein sequences. This analysis revealed that probands with LGD mutations in the same exon often had similar IQs, despite being affected by truncating mutations separated by scores to hundreds of amino acids in protein sequence ( Fig. 3a; Supplementary Fig. 3) . Notably, probands with LGD mutations in the same exon were more phenotypically similar than probands with LGD mutations separated by comparable amino acid distances but in different exons (FSIQ/NVIQ/VIQ distance-matched permutation test P = 0.010, 0.002, 0.018; Supplementary Fig. 4 ). We also investigated whether de novo mutations truncating a larger fraction of protein sequences resulted, on average, in more severe intellectual phenotypes. The analysis showed no significant correlations between the fraction of truncated protein and the severity of intellectual phenotypes (Fig. 3b) ; FSIQ/NVIQ/VIQ Pearson's R = 0.05, 0.05, 0.06 (P = 0.35, 0.35, 0.28; Supplementary Fig. 5 ). We also did not find any significant biases in the distribution of truncating de novo mutations across protein sequences compared with the distribution of synonymous de novo mutations (Kolmogorov-Smirnov two-tail test P = 0.9; Supplementary Fig. 6 ). The results presented above suggest that it is the occurrence of de novo LGD mutations in the same exon, rather than simply the proximity of mutation sites in nucleotide or amino acid sequence, that leads to similar phenotypic consequences. To explain this observation, we hypothesized that truncating mutations in the same exon usually affect, due to nonsense-mediated decay (NMD) 14 , the expression of the same splicing isoforms. Therefore, such mutations should lead to similar functional impacts through similar effects on overall gene dosage and the expression levels of affected transcriptional isoforms. To explore this mechanistic model, we used data from the Genotype and Tissue Expression (GTEx) Consortium 15, 16 , which collected exome sequencing and human tissue-specific gene expression data from hundreds of individuals and across multiple tissues. Using ~4, 400 LGD variants in coding regions and corresponding RNA-seq data, we compared the expression changes resulting from LGD variants in the same and different exons of the same gene (Fig. 4) . For each truncating variant, we analyzed allele-specific read counts 17 and then used an empirical Bayes approach to infer the effects of NMD on gene expression (see Methods) . This analysis demonstrated that the average gene dosage changes were more than 7 times more similar for individuals with LGD variants in the same exon compared to individuals with LGD variants in different exons of the same gene (Fig 4a) ; 2.2% versus 17.3% average difference in overall gene dosage decrease (Mann-Whitney U one-tail test P ˂ 2×10 -16 ). Moreover, by analyzing GTEx data for each tissue separately, we consistently found drastically more similar dosage changes resulting from LGD variants in the same exons (Fig. 4a) .
Distinct splicing isoforms often have different functional properties 18, 19 . Consequently, LGD variants may affect phenotypes not only through NMD-induced changes in overall gene dosage, but also by altering the expression levels of different splicing isoforms. To analyze changes in the relative expression of specific isoforms, we used GTEx variants and calculated the angular distance metric between vectors describing isoform-specific expression changes (see Methods). This analysis confirmed that changes in relative isoform expression are significantly (~5 fold) more similar for LGD variants in the same exon compared to variants in different exons (Fig. 4b) ; 0.1 versus 0.46 average angular distance (MannWhitney U one-tail test P ˂ 2×10 -16 ). The results were also consistent across tissues (Fig. 4b) . Overall, the analyses of GTEx data demonstrate that the changes in expression due to truncating variants in the same exon are indeed substantially more similar than the changes due to variants in different exons of the same gene. The average difference in isoformspecific expression change due to GTEx LGD variants. Differences in expression change across transcriptional isoforms were quantified using the angular distance metric between vectors representing isoform-specific expression changes. The average differences in isoform expression were calculated for LGD variants in the same exon (red bars) and in the same gene but different exons (blue bars) across human tissues. The height of each bar represents the average angular distance between isoform-specific expression changes across pairs of variants. Error bars represent the SEM.
Truncating variants in highly expressed exons should lead, through NMD, to relatively larger decreases in overall gene dosage. To confirm this hypothesis, we used RNA-seq data from GTEx to quantify the relative exon expression for each exon harboring a truncating variant. To calculate relative exon expression, we normalized GTEx expression values of each exon by GTEx expression values of the corresponding gene. Indeed, we observed a strong correlation between the relative expression levels of exons harboring LGD variants and the corresponding changes in overall gene dosage ( Fig. 5; Pearson's R = 0.69, P < 2×10 -16 ; Spearman's ρ = 0.81, P < 2×10 -16 ; see Methods). Exon-dependent dosage changes should also lead to population-wide depletion of LGD variants in highly expressed exons across human genes. Using data from the Exome Aggregation Consortium 20 , we indeed found that the rates of observed LGD variants decrease proportionally to exon expression (Supplementary Fig. 7 ).
Figure 5:
Relationship between the relative expression of exons containing LGD variants and the variantinduced decrease in overall gene expression. Each point corresponds to an LGD variant from the Genotype and Tissue Expression (GTEx) Consortium dataset, with gene and exon expression measured in one of ten human tissues. The x-axis represents the relative expression of the exon harboring the LGD variant in a tissue; the relative exon expression was calculated as the ratio between exon expression and total gene expression (see Methods). The y-axis represents the decrease in overall gene expression due to nonsensemediated decay (see Methods). Red line represents a moving average of the data.
Notably, NMD-induced dosage changes may mediate the relationship between the expression levels of target exons and the corresponding phenotypic effects of truncating mutations. To investigate this relationship we used the BrainSpan dataset 21 , which contains exon-specific expression from human brain tissues. The BrainSpan data allowed us to estimate expression dosage changes resulting from LGD mutations in different exons of ASD-associated genes (see Methods). Notably, it is likely that there is substantial variability in the sensitivity of intellectual phenotypes to dosage changes across human genes. Therefore, to quantify the IQ sensitivities for genes with recurrent truncating mutations in SSC, we considered a simple linear dosage model. Specifically, we assumed that changes in probands' IQs are linearly proportional to decreases in gene dosage; we further assumed the average neurotypical IQ (100) for wild type gene dosage. Using this model, we estimated the sensitivity of IQs to dosage changes for each gene with recurrent truncating ASD mutations (Supplementary Fig. 8 ; see Methods). Calculated in this way, the IQ sensitivity for a gene is equal to the estimated phenotypic effect of a truncating mutation in an exon with average expression. We then normalized the observed phenotypic effects of each mutation by the target gene's IQ sensitivity. This analysis revealed that mutation-induced dosage changes are indeed strongly correlated with the normalized phenotypic effects; FSIQ/NVIQ/VIQ Pearson's R = 0.56, 0.65, 0.51, permutation test P = 0.03, 0.017, 0.02; (Fig. 6a; Supplementary Fig. 9 ). Reassuringly, no or very weak correlations were obtained using randomly permuted data, i.e. when truncating mutations were randomly re-assigned to different exons in the same gene (average FSIQ/NVIQ/VIQ Pearson's R = 0.10, 0.16, 0.00; SD = 0.22, 0.20, 0.21; see Methods). Since the heritability of intelligence is known to significantly increase with age 22 , we also investigated how the results depend on the age of probands. When we restricted our analysis to the older half of probands in SSC (median age 8.35 years), the strength of the correlations between the predicted dosage changes and normalized phenotypic consequences increased further; FSIQ/NVIQ/VIQ Pearson's R = 0.71, 0.78, 0.63; permutation test P = 0.03, 0.016, 0.04 ( Fig. 6b; Supplementary Fig. 10 ). The strong correlations between target exon expression and intellectual ASD phenotypes suggest that, when gene-specific effects are taken into account, a significant fraction (30%-40%) of the relative phenotypic effects of de novo LGD mutations can be explained by the resulting dosage changes in target genes.
Next, we evaluated the ability of our linear dosage model to predict the effects of LGD mutations on non-normalized IQs. For each gene with multiple truncating mutations, we used our regression model to perform leave-one-out predictions of each mutation's effect on proband IQ scores ( Fig. 6c, inset ; see Methods). Notably, the prediction errors of the dosage model were significantly smaller than the differences in IQ scores between probands with LGD mutations in the same gene; FSIQ/NVIQ/VIQ median prediction error 13.7, 10.8, 22.0 points; same gene median IQ difference 24.0, 22.0, 30.5 points; MWU one-tail test P = 0.017, 0.009, 0.03 ( Fig. 6c; Supplementary Fig. 11 ). The predictions based on probands of the same gender had significantly smaller errors compared to predictions based on probands of the opposite gender, confirming functional differences in ASD genetics between genders; same gender FSIQ/NVIQ/VIQ median error 11.4, 9.9, 20.7 points; different gender median error 19, 17, 31.3 points (MWU one-tail test P = 0.08, 0.015, 0.05). Moreover, the prediction errors decreased for older probands; for example, for probands older than 12 years, median FSIQ/NVIQ/VIQ error 7.3, 7.6, 10.0 points (Fig. 6c,  Supplementary Fig. 11, Supplementary Fig. 12 ). Although we primarily analyzed the impact of ASD mutations on intellectual phenotypes, similar dosage and isoform expression changes in affected genes may also lead to analogous patterns for other phenotypes 23, 24 . Indeed, we observed similar results for several other key ASD phenotypes (Fig. 7) . For example, probands with truncating mutations in the same exon exhibited more similar adaptive behavior abilities compared to probands with mutations in the same gene (Fig. 7a, Supplementary Fig. 13) ; Vineland Adaptive Behavior Scales, composite standard score of 6.9 versus 12 points average differences (MannWhitney U one-tail test P = 0.04). Likewise, motor skills were more similar for probands with truncating mutations in the same exon (Fig. 7b) ; Purdue Pegboard Test, 1.2 versus 3.0 for the average difference in normalized tasks completed with both hands (MWU one-tail test P = 0.02, Supplementary Fig. 14 , see Methods). The age at which probands first walked was also more similar; median difference of 1 versus 3 months (MWU one-tail test P = 0.1). Finally, coordination scores in the Social Responsiveness Scale questionnaire were more closely related (Fig. 7c) ; 0.6 versus 1.1 for the average difference in normalized response (MWU one-tail test P = 0.05; Supplementary Fig. 15 ). 
Discussion
Previous studies explored phenotypic similarity in syndromic forms of ASD due to mutations in specific genes [25] [26] [27] [28] [29] . Nevertheless, across a large collection of contributing genes, the nature of the substantial phenotypic heterogeneity in ASD remains unclear. Our study reveals several main sources of the observed heterogeneity in simplex ASD cases triggered by highly penetrant truncating mutations. There is a substantial variability in the IQ sensitivity to dosage and isoform expression changes across human genes (Supplementary Fig. 8 ). We also estimate that, due to the imperfect efficiency of NMD, truncating mutations usually result in relatively mild changes in gene dosage, with the average decrease in overall expression ~15-30% (Supplementary Fig. 16 ; see Methods). Nevertheless, when gene-specific sensitivities are taken into account, the relative phenotypic effects are significantly correlated with expression dosage changes, which depend on the target exon expression (Fig. 6) . Furthermore, even perturbations leading to similar dosage changes in the same gene may result in diverse phenotypes, if different functional isoforms are affected. When the same isoforms are perturbed, as is the case for LGD mutations in the same exon, the phenotypic diversity in unrelated probands decreases even further (Fig.  2) . Overall, these results demonstrate that for truncating de novo mutations, exons, rather than genes, represent a unit of effective phenotypic impact. It is also likely that differences in genetic background and environment represent other important sources of phenotypic variability [30] [31] [32] . As the heritability of IQ phenotypes usually increases with age, it is reassuring that we observe a substantially higher correlation between phenotypes and gene dosage changes for older probands (Fig. 6b) .
In the present study, we focused specifically on simplex cases of ASD, in which de novo LGD mutations are highly penetrant. In more diverse cohorts, individuals with LGD mutations in the same exon will likely display substantially greater phenotypic heterogeneity. For example, the Simons Variation in Individuals Project identified broad spectra of phenotypes associated with specific variants in the general population [33] [34] [35] [36] . We also observed significantly larger phenotypic variability for probands from sequenced family trios, i.e. families without unaffected siblings (Supplementary Fig. 17 ). For these probands, the enrichment of de novo LGD mutations is likely to be substantially lower and the contribution from genetic background larger 37 , thus resulting in more pronounced phenotypic variability. Our study may have important implications for the future of precision medicine 30, 38, 39 . From a therapeutic perspective, compensatory expression increases of undamaged alleles -defined according to mutation-specific dosage changes -may provide a general approach for treating ASD probands affected by highly penetrant LGDs. From a prognostic perspective, the results suggest that by sequencing and phenotyping sufficiently large patient cohorts harboring truncating mutations in different exons of contributing ASD genes, it may be possible to understand likely phenotypic consequences, at least for cases resulting from highly penetrant de novo LGD mutations in simplex families. Furthermore, because we observe similar patterns of expression changes across multiple human tissues, medically relevant phenotypic analyses may be also extended to other developmental disorders caused by highly penetrant truncating mutations.
